drugset / Trial / NCT05324163

Evaluate Efficacy and Safety of X0002 in Treatment of Knee Osteoarthritis

NCT05324163

Phase 3 Completed 180 enrolled Jiangsu XinChen-Techfields Pharma Co., LTD.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a randomized, double-blind clinical trial in a Chinese population

Timeline

Start
2021-09-29
Primary completion
2023-02-06
Completion
2023-02-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 200 mg
Subject IBUPROFEN TRELAMINE Small molecule 17.5 mg

Indications